Brentuximab vedotin followed by bendamustine supercharge for refractory or relapsed Hodgkin lymphoma

Authors :: Novella Pugliese
Massimo Mascolo
Claudia Giordano
Chiara Mortaruolo
I. Cappuccio
Marco Picardi
M.G. Rascato
Fabio Trastulli
Maria Monteverde
Fabrizio Pane
R. Della Pepa
M. Memoli
Marta Raimondo
Picardi, M.
Della Pepa, R.
Giordano, C.
Pugliese, N.
Mortaruolo, C.
Trastulli, F.
Rascato, MARIA GABRIELLA
Cappuccio, Ilaria
Raimondo, M.
Memoli, M.
Monteverde, M.
Mascolo, M.
Pane, F.
Publication Year :: 2019
Abstract: We evaluated the impact on progression-free survival (PFS) of achieving a deep metabolic response at 2-deoxy-2[(18)F] fluoro-d-glucose positron emission tomography (FDG-PET) in patients with refractory or relapsed (R/R) classic Hodgkin lymphoma (cHL) following a new salvage regimen named Bv+Bs (brentuximab vedotin + bendamustine supercharge), from 2013 to 2017. In this real-life study, 20 consecutive patients (aged

Tools